Pharmaceutically acceptable salt as renal outer medullary potassium channel inhibitor

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11059810
APP PUB NO 20200123135A1
SERIAL NO

16305644

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A pharmaceutically acceptable salt as a renal outer medullary potassium channel (ROMK) inhibitor, specifically an L-tartrate and a crystal form I and crystal form II thereof, is described. The pharmaceutically acceptable salt of the ROMK inhibitor, specifically the L-tartrate, has improved bioavailability and stability.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
JIANGSU HENGRUI MEDICINE CO LTD222047 NO 7 KUNLUN SHAN ROAD LIANYUNGANG ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE JIANGSU LIANYUNGANG CITY JIANGSU PROVINCE 222047

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Feng, Jun Jiangsu, CN 210 4080
Lu, Yun Jiangsu, CN 33 226
Shao, Qiyun Jiangsu, CN 12 0
Wu, Guaili Jiangsu, CN 17 25

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 13, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 13, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00